Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Chemoradiotherapy for Recurrent Esophageal Cancer
NCT04390945Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in esophageal cancer, sponsored by First Affiliated Hospital of Henan University of Science and Technology. Primary endpoint: Progression-free survival at 9 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT04390945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390945.